$77.3 Million is the total value of Versant Venture Management, LLC's 8 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | $26,927,118 | -20.8% | 498,558 | 0.0% | 34.84% | +5.7% | |
| New | Contineum Therapeutics, Inc. | $16,168,850 | – | 918,163 | +100.0% | 20.92% | – | |
| Buy | Skye Bioscience, Inc. | $16,081,709 | -48.8% | 2,007,704 | +0.0% | 20.80% | -31.7% | |
| RPTX | Repare Therapeutics, Inc. | $8,733,968 | -29.9% | 2,646,657 | 0.0% | 11.30% | -6.5% | |
| ADVM | Sell | Adverum Biotechnologies, Inc. | $3,476,792 | -51.5% | 506,821 | -0.0% | 4.50% | -35.3% |
| PASG | Sell | Passage Bio, Inc. | $3,197,780 | -52.2% | 4,026,417 | -18.8% | 4.14% | -36.3% |
| GRTS | Gritstone Oncology, Inc. | $2,200,435 | -76.0% | 3,561,150 | 0.0% | 2.85% | -67.9% | |
| ALGS | Sell | Aligos Therapeutics, Inc. | $510,278 | -77.6% | 1,457,937 | -37.2% | 0.66% | -70.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-07
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 35 | Q2 2023 | 10.2% |
| Clovis Oncology, Inc. | 32 | Q3 2022 | 53.2% |
| CRISPR Therapeutics AG | 26 | Q2 2024 | 77.2% |
| Ocular Therapeutix, Inc. | 22 | Q4 2020 | 18.0% |
| Gritstone Oncology, Inc. | 21 | Q2 2024 | 25.4% |
| Achaogen, Inc. | 18 | Q1 2019 | 23.5% |
| Adverum Biotechnologies, Inc. | 18 | Q2 2024 | 21.0% |
| Aligos Therapeutics, Inc. | 15 | Q2 2024 | 15.7% |
| Second Sight Medical Products, Inc. | 15 | Q3 2020 | 9.0% |
| Passage Bio, Inc. | 14 | Q2 2024 | 21.8% |
View Versant Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-11-08 |
| N-PX | 2024-08-13 |
| 13F-HR | 2024-08-07 |
| 13F-HR | 2024-05-03 |
| 13F-HR | 2024-02-08 |
| 13F-HR | 2023-11-03 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-11 |
| 144 | 2023-04-20 |
| 13F-HR | 2023-02-09 |
View Versant Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.